Shenzhen Hepalink Pharmaceutical Group Co Ltd Sustainability Reports
The company operates across the entire industrial chain of heparin, providing heparin API and biosimilar enoxaparin sodium injections globally. It also offers comprehensive CDMO services for large biological molecules and invests in innovative drug development.
Sector: Manufacturing
Country: China
Exchange: Shenzhen Stock Exchange
ISIN: CNE100000P02
9 reports from 2020 to 2025
- Shenzhen Hepalink Pharmaceutical Group Co Ltd 2025 Environmental, Social and Governance Report
- Shenzhen Hepalink Pharmaceutical Group Co Ltd 2024 Annual Report
- Shenzhen Hepalink Pharmaceutical Group Co Ltd 2024 ESG Report
- Shenzhen Hepalink Pharmaceutical Group Co Ltd 2023 Annual Report
- Shenzhen Hepalink Pharmaceutical Group Co Ltd 2023 ESG Report